TELA Bio, Inc. (NASDAQ: TELA) reported Q2 EPS of ($0.22), $0.04 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $20.2 million versus the consensus estimate of $20.67 million.

For earnings history and earnings-related data on TELA Bio, Inc. (TELA) click here.